Notably, the PARP1 inhibitor Olaparib significantly reduces tumor burden in Nudt13VillKO mice, implying that CRC patients with low NUDT13 protein levels may benefit from Olaparib treatment. The gene discussed is PARP1; the disease is neoplasm.